There's an experimental hormonal agent, code named VT-464. It has a dual mode of action:
(1)it blocks production of androgens by the adrenals and within the tumor, which is what Zytiga does, and
(2)it blocks the androgen receptor, which is what Xtandi does.
The hope is that by blocking both pathways simultaneously, it may work better than Zytiga or Xtandi alone. Also, it may work even after those have failed, possibly overcoming the cross-resistance that can happen with the other drugs.
This is a Phase 2 clinical trial, so everyone gets the pills. It is being tried at several institutions around the US & Europe, so there may be one near you. Some haven't started up yet, but will come on board soon. If you're interested, call the number in the link. Even if they haven't started up yet, they can tell you about
it and possibly get you on a wait list.Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or AbirateroneOral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With EnzalutamideA Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer